A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...